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Quantitative analysis of human
endogenous retrovirus-K transcripts
in postmortem premotor cortex fails
to confirm elevated expression of HERV-K
RNA in amyotrophic lateral sclerosis
Jeremy A. Garson1,2* , Louise Usher3, Ammar Al-Chalabi4, Jim Huggett5,6, Edmund F. Day3 and
Adele L. McCormick3
Abstract
Over the past two decades a number of studies have demonstrated activity of the retroviral enzyme reverse
transcriptase in the serum of patients with sporadic amyotrophic lateral sclerosis (ALS). Known human exogenous
retroviruses such as HIV-1 have been eliminated as possible sources of this activity and investigators have therefore
considered the possibility that human endogenous retroviruses (HERVs) might be involved. HERV-K (HML-2) is the
most recent retroviral candidate to be proposed following the observation of elevated HERV-K expression in cortical
and spinal neurons of ALS patients and the demonstration of HERV-K envelope protein neurotoxicity in vitro and in
transgenic mice. This retroviral hypothesis is an attractive one, not least because it raises the possibility that ALS
might become treatable using antiretroviral drugs. In the present study we have attempted independent
confirmation of the observation that HERV-K RNA levels are elevated in ALS brain. Total RNA was extracted from the
postmortem premotor cortex of 34 patients with ALS and 23 controls. Quantitative real-time reverse transcription
PCR (RT-qPCR) was performed according to the MIQE guidelines using HERV-K gag, pol and env primer sets. Data
was analysed by the 2-ΔΔCt method with normalisation against two reference genes, GAPDH and XPNPEP1.
Geometric mean HERV-K RNA expression levels in the premotor cortex of ALS patients were not found to be
different from the expression levels in non-ALS controls. Our findings do not confirm the recently reported
association between elevated cortical HERV-K RNA levels and ALS, and thus raise doubts about the role of this
endogenous retrovirus in ALS pathogenesis. The results of this study may have implications for ongoing clinical
trials aiming to suppress HERV-K activity with antiretroviral drugs.
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Introduction
Amyotrophic lateral sclerosis (ALS), also known as
motor neuron disease, is a fatal neurodegenerative dis-
ease characterised by loss of motor neurons from the
brain and spinal cord. In Europe and the USA the
incidence is about 2 cases per 100,000 person-years and
survival post diagnosis is typically 3 to 5 years. In about
5–10% a family history of ALS may be obtained in a first
or second degree relative. Variants causative of or associ-
ated with ALS have been identified in at least 25 differ-
ent genes, and in people with or without a family
history, but the aetiology of most apparently sporadic
cases remains uncertain [6].
Numerous non-genetic environmental risk factors for
apparently sporadic ALS have been proposed including
electromagnetic fields, heavy metals, pesticides, smoking,
dietary factors, physical trauma and viral infection [16].
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Enteroviruses and herpesviruses have been considered [5,
8] but more recent attention has focused on retroviruses.
Retroviruses are known to cause motor neuron disease in
mice [12], and the human retroviruses HIV-1 and
HTLV-1 are both capable of causing ALS-like syndromes
[23, 32], which in some cases have been shown to respond
well to antiretroviral therapy [1, 22].
In a series of studies looking directly for evidence of
retroviral involvement in ALS we have been able to ex-
clude known exogenous retroviruses whilst repeatedly
demonstrating an increased prevalence and raised levels
of reverse transcriptase activity (a generic retroviral
marker) in the serum of patients with ALS [3, 4, 25, 29].
The increased prevalence of reverse transcriptase activity
in ALS was subsequently confirmed independently by
another group [21]. In one of our studies [29] reverse
transcriptase activity was detected more frequently in
the serum of unaffected blood relatives of ALS pa-
tients than in unrelated controls and spouses. This
raised the possibility that the observed reverse tran-
scriptase activity might be associated with an inher-
ited endogenous retrovirus.
Human endogenous retroviruses (HERVs), which con-
stitute around 8% of the human genome, are thought to
be the relics of retroviral germline infections that oc-
curred millions of years ago [14]. Most HERVs are con-
sidered inactive due to the accumulation of mutations
and deletions but there is increasing evidence that some
of them may be capable of expressing full-length RNA
transcripts, proteins and even retroviral particles. The
most recently integrated HERVs such as HERV-K
(HML-2) are thought to be the most intact and poten-
tially biologically active [30] and it was therefore of great
interest when elevated HERV-K RNA levels were re-
ported in the cerebral cortex of patients with ALS [9,
19]. In addition to increased cortical HERV-K RNA, Li
et al. [19] reported that HERV-K envelope protein was
selectively expressed in cortical and spinal neurons of
ALS patients and that the envelope protein was neuro-
toxic in stem-cell derived human neurons and in a
transgenic mouse ALS model, strongly suggesting that
HERV-K contributes to motor neuron disease.
In the present study we have attempted independent
confirmation of elevated HERV-K transcripts in the cor-
tex of ALS patients by using exactly the same GAPDH
(Glyceraldehyde 3-phosphate dehydrogenase)-norma-
lised RT-qPCR methods for quantification of HERV-K
gag, pol and env transcripts as those described previously
[19]. We have also repeated the quantification of cortical
HERV-K transcripts using an alternative validated refer-
ence gene, XPNPEP1 (X-prolyl aminopeptidase 1), as
recommended by the MIQE guidelines [7]. Additionally,
we investigated HERV-W, which has previously been as-
sociated with multiple sclerosis, schizophrenia and
chronic inflammatory demyelinating polyneuropathy
[17], in the same ALS and control samples by estimating
its env RNA expression using a similar RT-qPCR
method, to exclude it as a possible cause of the previ-




Frozen postmortem brain material was obtained from
the Medical Research Council (MRC) Neurodegenerative
Disease Brain Bank Network, Institute of Psychiatry,
Psychology and Neuroscience, Kings College London,
UK. Premotor cortex (i.e. part of the frontal lobe just
anterior to the primary motor cortex) from 34 patients
with sporadic ALS and 23 non-ALS controls was
analysed. Details including age, gender, diagnosis, post-
mortem delay and RNA integrity number (RIN) are pre-
sented in Additional file 1: Table S1. All ALS patients
had their ALS clinical diagnosis confirmed by neuro-
pathological examination of the brain postmortem.
RNA extraction and quality control
60mg pieces of frozen (− 80 °C) premotor cortex were
homogenised (TissueRuptor II, Qiagen Ltd., Crawley, UK)
on dry ice in QIAzol lysis buffer (Qiagen) and extracted
using the RNeasy Lipid Tissue kit (Qiagen) with
on-column DNase treatment (RNase-free DNase Set, Qia-
gen) according to the manufacturer’s instructions. RNA
concentration was measured by Qubit™ RNA BR assay
(Thermo Fisher Scientific Inc. Waltham, MA, USA) and
RNA quality established by Agilent RNA 6000 Nano assay
(Agilent Technologies, Inc. Santa Clara, CA, USA).
cDNA synthesis
Reverse transcription of 1 μg of total RNA in a 20 μl
reaction was performed using the Invitrogen SuperScript
III First-Strand Synthesis Supermix for qRT-PCR
(Thermo Fisher) according to manufacturer’s instruc-
tions. RNase H digestion was carried out at 37 °C for 20
mins and cDNA stored at − 20 °C. Negative control re-
verse transcription reactions without adding RNA were
included in each batch of cDNA syntheses.
HERV-K RT-qPCR
Real-time PCR was performed in an Applied Biosystems
QuantStudio™ 5 thermocycler (Thermo Fisher), 96 well
format, using Fast SYBR Green Master Mix (Thermo
Fisher) in a 20 μl reaction with 2 μL cDNA and final
concentrations of 0.25 μM forward primer and 0.25 μM
reverse primer or 1X primer pool for XPNPEP1. Primer
sequences for amplification of HERV-K gag, pol and env,
and GAPDH were as described previously [19] and de-
tailed in Table 1. Thermal cycling parameters were as
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follows: DNA polymerase activation, 95 °C for 20 s, then
45 cycles of denaturation, 95 °C for 1 s and anneal/exten-
sion 60 °C for 20 s. Cycling was followed by melt curve
analysis. Automatic baseline settings were used with a
manual threshold setting of 0.2 in all experiments. Each
sample was analysed in duplicate and any sample with a
Cq (quantification cycle) standard deviation of > 0.2 was
repeated. All 96 well plates contained samples from both
ALS patients and control individuals. No template con-
trols (NTCs) were run in each experiment and every
sample was analysed with and without reverse transcrip-
tion in order to identify any residual genomic DNA con-
tamination in the extracted RNA. Relative HERV-K
RNA expression levels (i.e. relative with respect to the
geometric mean of the non-ALS controls) were calcu-
lated using the 2-ΔΔCt method [20] by normalisation
against both GAPDH and XPNPEP1 reference tran-
scripts. RT-qPCR procedures were performed in accord-
ance with the MIQE guidelines [7] (Additional file 1:
Table S2) and all experiments were conducted ‘blind’
with the identity of each sample being hidden from the
investigator. RT-qPCR experiments were conducted sim-
ultaneously on ALS cases and controls so as to eliminate
such confounders as batch effects.
HERV-W RT-qPCR
HERV-W env RNA was quantified in all samples by the
same method used for HERV-K RNA quantification but
using the HERV-W env specific primers (Table 1) de-
scribed previously [18].
Reference gene validation
A panel of 9 candidate reference gene primer sets were
evaluated in order to establish the one with the most
stable level of expression in ALS and non-ALS control
premotor cortex samples. Briefly, RT-qPCR was used to
quantify the RNA expression levels of GAPDH, ACTB,
CYC1, SDHA, UBC, RPL13A, XPNPEP1, EIF4A2 and
YWHAZ in 5 ALS samples and 5 non-ALS control sam-
ples in triplicate. All primer sets apart from XPNPEP1
were obtained from Primerdesign Ltd., Camberley, UK.
The evaluation was conducted using qBase+ software,
version 3.1 (Biogazelle, Zwijnaarde, Belgium), which uti-
lises the geNorm selection algorithm [31], along with
additional statistical tools. Further verification was per-
formed using RefFinder software [33] which exploits the
computational programs Normfinder [2], BestKeeper
[27], geNorm and the ΔCt method [28] to comprehen-
sively rank and compare candidate reference genes.
Sequencing
Amplicons generated by the HERV-K gag, HERV-K pol,
HERV-K env, HERV-W env, GAPDH and XPNPEP1 PCRs
were subjected to Sanger dideoxy sequencing (Eurofins
GTAC Biotech, Germany) and sequences analysed by
BLAST (Basic Local Alignment Search Tool) in order to
check the specificity of each assay. In each case amplicon
size was confirmed by agarose gel electrophoresis.
Statistical analysis
The statistical significance of differences between groups
was assessed by 2-tailed Mann-Whitney U test (GraphPad
Prism 7 software). p-values of < 0.05 were considered sig-
nificant. Linear regression p-values were calculated using
Microsoft Excel Add-In Daniel’s XL toolbox v6.22.
Results
Matching of ALS patients with non-ALS control group
Due to limited availability of suitable postmortem mater-
ial it was not always possible to obtain a perfect match
Table 1 Oligonucleotide sequence information
Primer name Sequence 5′-3’ Reference
HERV-K gag forwarda AGCAGGTCAGGTGCCTGTAACATT Li et al., [19]
HERV-K gag reverse TGGTGCCGTAGGATTAAGTCTCCT Li et al., [19]
HERV-K pol forward TCACATGGAAACAGGCAAAA Li et al., [19]
HERV-K pol reverse AGGTACATGCGTGACATCCA Li et al., [19]
HERV-K env forward CTGAGGCAATTGCAGGAGTT Li et al., [19]
HERV-K env reverse GCTGTCTCTTCGGAGCTGTT Li et al., [19]
GAPDH forward TGCACCACCAACTGCTTAGC Li et al., [19]
GAPDH reverse GGCATGGACTGTGGTCATGAG Li et al., [19]
XPNPEP1 forward Qiagen cat no. QT00051471 Qiagena
XPNPEP1 reverse Qiagen cat no. QT00051471 Qiagena
HERV-W env forward GTATGTCTGATGGGGGTGGAG Levet et al., [18]
HERV-W env reverse CTAGTCCTTTGTAGGGGCTAGAG Levet et al., [18]
aAll primers were synthesised by Eurofins Genomics (Germany) apart from the XPNPEP1 primers which were obtained from Qiagen (Hs_XPNPEP1_1_SG QuantiTect
Primer. Product number: 249900. Cat no: QT00051471)
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of all clinical parameters between the ALS patient group
and the non-ALS control group. The mean age at death
was 66.9 years for the ALS patients and 73.5 years for
the controls (p = 0.03). There was also a difference in
gender distribution between the ALS and control
groups. The ALS group was 29% female whereas the
control group was 48% female. There was no significant
difference in mean postmortem delay between the pa-
tients and controls; for the ALS group it was 45.1 h and
for the control group 41.7 h (p = 0.64). Finally, there was
a small difference between the mean RNA integrity value
(RIN) of the ALS samples, 6.53, and that of the controls,
6.05 (p = 0.01). The potential effect of such imperfectly
matched parameters on HERV-K expression compari-
sons between ALS patients and controls is considered
below.
RT-qPCR performance characteristics
Agarose gel electrophoresis confirmed that the ampli-
cons generated by each of the six different RT-qPCR as-
says (HERV-K gag, HERV-K pol, HERV-K env, HERV-W
env, GAPDH, XPNPEP1) were single bands of the ex-
pected size. Melt curve analysis also revealed single
dominant peaks for all assays. Amplification specificity
was further confirmed by Sanger sequencing of the
amplicons which demonstrated that the nucleotide se-
quence was as expected for all six RT-qPCR assays
(Basic Local Alignment Search Tool, BLASTn, analysis).
PCR efficiencies for each assay were estimated from
slopes of serial dilution standard curves using the for-
mula E = 10^(− 1/slope) – 1 and all fell within the range
99% ± 6%. For each assay the R2 value of the standard
curve was > 0.99. The no template controls were nega-
tive in all experimental runs and the no reverse tran-
scriptase controls revealed that residual genomic DNA
in RNA extracts typically contributed less than 1%, but
always less than 3%, of the total signal in all samples.
Reference gene validation
qBase+ and RefFinder ranking of the nine candidate ref-
erence genes revealed that XPNPEP1 and GAPDH had
the most stable expression in ALS and control samples
(Additional file 1: Table S3). XPNPEP1 was therefore se-
lected as the additional ‘validated’ reference gene to use
in addition to GAPDH for the normalisation of HERV-K
and HERV-W RNA expression levels.
HERV-K RNA expression in ALS and controls
Figure 1 and Table 2 summarise the relative expression
levels of HERV-K gag, pol and env RNA in the 34 ALS
cases and 23 non-ALS controls investigated. When the
GAPDH reference gene was used for normalisation, the
geometric mean expression levels for HERV-K gag and
HERV-K pol were very slightly higher in the ALS
a b c
d e f
Fig. 1 Relative expression levels of HERV-K gag, pol and env RNA in ALS and non-ALS controls. a, b, c normalised against GAPDH; d, e, f normalised
against XPNPEP1. Horizontal black lines represent geometric means. All p values are > 0.05, NS
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patients than in the control group but the converse was
true for HERV-K env. None of these marginal differences
in HERV-K expression levels approached statistical sig-
nificance. When the XPNPEP1 reference gene was used
for normalisation the geometric mean expression levels
for all three HERV-K genes were slightly lower in ALS
cases than in controls. Once again these small differ-
ences in geometric mean expression levels failed to
reach statistical significance. However, the expression
levels of HERV-K gag, pol and env were correlated with
each other whether the data was normalised by GAPDH
or XPNPEP1 reference genes (Fig. 2).
As perfect matching between the ALS patients and
non-ALS controls of parameters such as age, gender,
postmortem delay and RIN values was not always pos-
sible due to limited availability of suitable postmortem
material, these variables were also examined for possible
correlation with HERV-K expression. Neither age nor
gender was correlated with HERV-K gag, pol or env ex-
pression levels whether data was normalised by GAPDH
or XPNPEP1 reference genes (Additional file 1: Figure
S1 and Figure S2). A trend towards reduced HERV-K
RNA levels with increased postmortem delay was ob-
served (Additional file 1: Figure S3) for HERV-K pol and
Table 2 Geometric mean relative expression of HERV-K RNA in ALS cases and controls
HERV-K gag HERV-K pol HERV-K env HERV-K gag HERV-K pol HERV-K env
Normalisation methoda GAPDH GAPDH GAPDH XPNPEP1 XPNPEP1 XPNPEP1
ALS 1.001 1.025 0.975 0.868 0.888 0.845
Control 1 1 1 1 1 1
p value 0.677 0.671 0.990 0.113 0.095 0.055
Statistical significance NSb NS NS NS NS NS
a Normalisation against either GAPDH or XPNPEP1 reference genes
b NS = the difference was not statistically significant at p < 0.05
a b c
d e f
Fig. 2 Correlations between HERV-K gag, pol and env RNA relative expression levels. Data from all 34 ALS and 23 non-ALS controls are presented.
a, b, c normalised against GAPDH; d, e, f normalised against XPNPEP1. R-squared coefficient of determination values calculated in Microsoft Excel.
All p values are < 0.0001 by linear regression
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env, whether normalisation was to GAPDH or XPNPEP1
reference genes (p ≤ 0.01). RIN values were not corre-
lated with HERV-K gag, pol or env RNA levels when
GAPDH normalisation was used but there was a slight
negative correlation between high RIN values and
XPNPEP1-normalised relative HERV-K gag and env
RNA levels (gag, p = 0.04 and env, p = 0.03, Additional
file 1: Figure S4).
HERV-W env RNA expression in ALS and controls
Figure 3 shows the relative HERV-W env RNA expres-
sion levels in ALS cases and non-ALS controls. When
GAPDH was employed for normalisation, the geometric
mean HERV-W env RNA level for the ALS cases was
0.87 and for the controls 1.00 (p = 0.26). However, when
XPNPEP1 was used for normalisation the geometric
mean HERV-W env RNA level in ALS was lower at 0.75
than in controls at 1.00 (p = 0.04).
HERV-W env RNA levels showed no correlation with age
or gender whether normalised by GAPDH or XPNPEP1
(Additional file 1: Figure S5 and Figure S6). Postmortem
delay was not significantly correlated with HERV-W env
RNA levels when XPNPEP1 normalisation was used but
there was a downward trend of HERV-W env RNA level
with increased PMD when GAPDH normalisation was used
(p = 0.04) (Additional file 1: Figure S7). With XPNPEP1
normalisation, high RIN values were correlated with low
relative expression of HERV-W env RNA (p = 0.001) but
there was no correlation when GAPDH normalisation was
used (Additional file 1: Figure S8).
Correlation between GAPDH-normalised and XPNPEP1-
normalised expression data
GAPDH-normalised relative expression levels and XPNPEP1-
normalised relative expression levels correlated well with each
other for HERV-K gag, pol and env, and also for HERV-W
env transcripts (Additional file 1: Figure S9).
Discussion
Overexpression of HERV-K has recently been proposed as
a possible causative factor in patients with ALS [19]. Al-
though this is an attractive hypothesis, not least because it
raises the possibility that ALS might become treatable
using antiretroviral drugs [26] or antibodies [13], the con-
tribution of HERV-K to the disease process has yet to be
conclusively proven. The magnitude of the difference re-
ported previously [19] between the mean HERV-K RNA
expression level in ALS patients and non-ALS controls
was less than threefold for gag and env, and less than two
fold for pol. Although such relatively modest differences
can in principle be resolved by RT-qPCR due to the high
technical precision of the method, it is essential to demon-
strate their reproducibility in other patient cohorts by in-
dependent testing such as that undertaken here. In this
study we have therefore attempted confirmation of the ob-
servation that GAPDH-normalised HERV-K RNA levels
are elevated in the cerebral cortex of ALS patients with re-
spect to non-ALS controls. Postmortem premotor cortex
samples from 34 patients with ALS and 23 non-ALS con-
trols were tested using the same RT-qPCR methods (in-
cluding the same reverse transcription method, the same
DNase treatment method, the same PCR reagents and the
same thermal cycling parameters), the same 2-ΔΔCt data
analysis method and identical primer sets to those used
previously [19]. Our observations were concordant with
previous findings [19] regarding the good correlation be-
tween the relative expression levels of the three HERV-K
transcripts gag, pol and env, suggesting that the entire
viral genome was expressed. However, in contrast to
the findings of Li et al. [19], we were unable to
demonstrate any difference in HERV-K gag, pol or
a b
Fig. 3 Relative expression levels of HERV-W env RNA in 34 ALS and 23 non-ALS controls. (a) normalised against GAPDH; (b) normalised
against XPNPEP1. P value for the difference between the groups when normalised by GAPDH was p = 0.26 and when normalised by
XPNPEP1 was p = 0.04. Horizontal black lines represent geometric means
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env RNA levels between ALS patients and controls,
whether the data were normalised by GAPDH or
XPNPEP1 reference genes.
The reasons for this conflict are uncertain but several
possibilities exist. Firstly, our ALS patients and non-ALS
controls were not perfectly matched for age, gender,
postmortem delay or RIN values and the differences be-
tween the groups were statistically significant for age,
gender and RIN. However, none of these three parame-
ters was found to be correlated with GAPDH-normalised
HERV-K RNA expression and so their imperfect match-
ing does not appear to explain why our results differ
from those published previously [19]. Secondly, it is con-
ceivable that differences between the USA ALS cohort
[19] and our UK ALS cohort might explain the discrep-
ant results. We consider this unlikely because the diag-
nosis of ALS was confirmed by neuropathological
examination in both cohorts and tissue samples in the
two cohorts were derived from similar neuroanatomical
regions. Nevertheless, it is theoretically possible that
there is a small subset of ALS patients who do have ele-
vated cortical HERV-K expression and that members of
that subset were present in the ALS cohort studied by Li
et al. but not in our cohort. However, in comparison
with our ALS samples, the mean postmortem delay was
shorter and the mean RIN value was higher in the
samples analysed previously [19]. Although we found no
significant correlation between GAPDH-normalised
HERV-K RNA expression and RIN we did observe a
trend towards lower GAPDH-normalised HERV-K RNA
levels (pol and env only) with increasing postmortem
delay. Nevertheless, we consider it unlikely that this dif-
ference in mean postmortem delay explains our failure
to confirm the previously published findings [19] be-
cause the HERV-K RNA RT-qPCR quantitative data is
not ‘absolute’ but ‘relative’ with respect to the geometric
mean level of the non-ALS controls which had postmor-
tem delays not significantly different from the ALS cases.
In agreement with a previous report on human postmor-
tem brain RNA quality [11] we found no correlation
between RIN value and postmortem delay (Additional
file 1: Figure S10). Thirdly, it is conceivable that the dis-
crepancy may be related to differences in the proportion
of controls with cancer. Twenty five percent of the
control group used by Li et al. had cancer as against 47%
in the present study. Since upregulation of HERV-K
expression occurs in various types of tumour tissue [30]
it could be argued that there is a remote possibility that
HERV-K expression could be elevated in the brains of
the controls who had cancer, even without cerebral
metastases. However, this explanation can be dismissed
because our conclusion that patients with ALS do not
have significantly higher levels of cerebral HERV-K RNA
expression than non-ALS controls remains unchanged
on reanalysing the data following exclusion of those with
cancer from the control group (Additional file 1: Figure
S11). Finally, the relatively low number of ALS cases
studied by Li et al. (n = 11) may have resulted in less
statistically robust findings than those generated by our
larger analysis of 34 cases.
For ensuring accurate quantification, the importance
of selecting appropriate reference genes for normalisa-
tion in RNA expression studies has been stressed by
many authors, as has the advantage of using more than
one reference gene [7, 15]. In the present study we eval-
uated a panel of nine candidate reference genes includ-
ing GAPDH which had been used previously [19]. This
evaluation revealed that XPNPEP1 and GAPDH had the
most stable expression in ALS and non-ALS control
material, and XPNPEP1 was therefore chosen as the
additional reference gene. It is noteworthy that Durren-
berger et al. [10] in an evaluation of 12 candidate
reference genes for use on human CNS postmortem tis-
sue in various neurological diseases including ALS, also
identified XPNPEP1 as the most stable and suitable can-
didate. GAPDH-normalised relative expression levels
and XPNPEP1-normalised relative expression levels were
generally well correlated. Our conclusion that HERV-K
RNA levels are not elevated in the premotor cortex of
ALS patients with respect to non-ALS controls was the
same whichever reference gene was used for data
normalisation.
In the study by Li et al. [19], cerebral cortical expres-
sion of a number of other HERVs, in addition to
HERV-K, was measured. They examined HERV-E,
HERV-R and HERV-P by RT-qPCR but did not observe
significant ALS-associated elevation of transcripts in any
of these. We considered that HERV-W should also be
investigated because it had been implicated in a number
of other neurological conditions including multiple
sclerosis, schizophrenia and chronic inflammatory de-
myelinating polyneuropathy [17]. Although our study
does not show any association between HERV-W RNA
expression level and ALS when data is GAPDH-
normalised, a small negative correlation (p = 0.04) be-
tween HERV-W RNA expression and ALS was observed
with XPNPEP1 normalisation due in part to four control
samples showing relatively high HERV-W env expression
when normalised to this reference gene. We speculate
however that this small negative correlation may be un-
reliable due to our ALS samples having a slightly higher
mean RIN value than controls, in conjunction with high
RIN values being significantly correlated with lower
XPNPEP1-normalised relative HERV-W expression.
Another study investigating the potential role of
HERV-K in ALS has just been published by Mayer et al.
[24]. Using an alternative RT-qPCR method they exam-
ined levels of GAPDH-normalised HERV-K gag RNA in
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frozen postmortem neural tissues from a total of 108
ALS and control samples obtained from brain banks in
the USA. As in our study, Mayer and colleagues were
unable to confirm the previous findings [19] and
concluded that levels of HERV-K transcripts were not
significantly different between ALS and controls.
Furthermore, they were unable to demonstrate any
significant difference between ALS and controls in the
pattern of transcriptionally active HERV-K loci by
sequencing-based transcriptional profiling, or indeed any
evidence of full length HERV-K envelope protein in ei-
ther ALS or control tissues. These transcriptional profil-
ing results also conflict with the findings of Li et al. [19]
who observed three HERV-K loci to be transcribed at
higher levels in ALS cases than in controls. However, it
is important to note that the failure of our study and
that of Mayer et al. to confirm elevated levels of
HERV-K RNA in ALS post-mortem brain tissue does
not diminish the significance of the report by Li et al.
[19] that expression of HERV-K in human neurons in
vitro causes toxicity, or that expression of HERV-K env
in transgenic mice causes degeneration of motor
neurons and progressive motor dysfunction.
Conclusion
In conclusion, our observations and those recently pub-
lished by Mayer and colleagues [24] fail to confirm the
findings of Li et al. [19] and provide no support for the
hypothesis that elevated HERV-K expression in the cere-
bral cortex is associated with sporadic amyotrophic
lateral sclerosis. These conflicting results may have sig-
nificant implications for ALS clinical trials aiming to
suppress HERV-K activity with antiretroviral drugs, and
suggest that further research in this area is required to
discover the source of the increased serum reverse tran-
scriptase activity seen in this disease. Future studies that
we propose include the use of next generation sequen-
cing and custom-made microarrays to undertake a broad
screening of the expression profiles of all human en-
dogenous retrovirus families in ALS and controls.
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